Coherus Oncology, Inc. (CHRS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in CapitalUSD $1.50B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-281.00K; Retained Earnings (Accumulated Deficit)USD $-1.44B.
- 2026-03-31: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in CapitalUSD $1.50B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-268.00K; Retained Earnings (Accumulated Deficit)USD $-1.42B.
- 2025-12-31: Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.44B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-195.00K; Retained Earnings (Accumulated Deficit)USD $-1.38B.
- 2025-09-30: Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.43B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-203.00K; Retained Earnings (Accumulated Deficit)USD $-1.35B.
Coherus Oncology, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.00K | $1.50B | $-281.00K | $-1.44B | $60.84M | (m) | 3 month · $2.60M | (m) | (m) |
| 2026-03-31 | $15.00K | $1.50B | $-268.00K | $-1.42B | $78.62M | (m) | 3 month · $2.41M | (m) | (m) |
| 2025-12-31 | $12.00K | $1.44B | $-195.00K | $-1.38B | $61.01M | (m) | 12 month · $16.91M | (m) | (m) |
| 2025-09-30 | $12.00K | $1.43B | $-203.00K | $-1.35B | $87.77M | (m) | 3 month · $3.40M | (m) | (m) |
| 2025-06-30 | $12.00K | $1.43B | $-275.00K | $-1.31B | $119.83M | (m) | 3 month · $5.36M | (m) | (m) |
| 2025-03-31 | $12.00K | $1.42B | $-275.00K | $-1.61B | $-183.47M | (m) | 3 month · $5.35M | (m) | (m) |
| 2024-12-31 | $12.00K | $1.42B | $-275.00K | $-1.55B | $-131.99M | (m) | 12 month · $28.35M | (m) | (m) |
| 2024-09-30 | $12.00K | $1.41B | $-275.00K | $-1.50B | $-87.97M | (m) | 3 month · $6.90M | (m) | (m) |
| 2024-06-30 | $12.00K | $1.41B | $-272.00K | $-1.49B | $-84.11M | 3 month · $52.00K | 3 month · $7.33M | (m) | (m) |
| 2024-03-31 | $11.00K | $1.40B | $-272.00K | $-1.48B | $-81.84M | (m) | 3 month · $7.68M | (m) | (m) |
| 2023-12-31 | $11.00K | $1.39B | $-248.00K | $-1.58B | $-193.43M | (m) | 12 month · $43.54M | (m) | (m) |
| 2023-09-30 | $11.00K | $1.37B | $-265.00K | $-1.50B | $-133.60M | (m) | 3 month · $10.15M | (m) | (m) |
| 2023-06-30 | $9.00K | $1.29B | $-297.00K | $-1.46B | $-174.76M | (m) | 3 month · $10.03M | (m) | (m) |
| 2023-03-31 | $8.00K | $1.22B | $-278.00K | $-1.42B | $-196.51M | (m) | 3 month · $12.29M | (m) | (m) |
| 2022-12-31 | $8.00K | $1.20B | $-249.00K | $-1.34B | $-137.42M | (m) | 12 month · $51.19M | (m) | (m) |
| 2022-09-30 | $7.00K | $1.19B | $-270.00K | $-1.28B | $-97.13M | (m) | 3 month · $12.39M | (m) | (m) |
| 2022-06-30 | $7.00K | $1.17B | $-270.00K | $-1.20B | $-22.63M | (m) | 3 month · $13.94M | (m) | (m) |
| 2022-03-31 | $7.00K | $1.16B | $-272.00K | $-1.15B | $12.56M | (m) | 3 month · $13.04M | (m) | (m) |
| 2021-12-31 | $7.00K | $1.15B | $-270.00K | $-1.05B | $97.73M | (m) | 12 month · $51.29M | (m) | (m) |
| 2021-09-30 | $7.00K | $1.14B | $-273.00K | $-1.00B | $130.76M | (m) | 3 month · $11.79M | (m) | (m) |
| 2021-06-30 | $7.00K | $1.12B | $-267.00K | $-965.60M | $156.22M | (m) | 3 month · $11.51M | (m) | (m) |
| 2021-03-31 | $7.00K | $1.06B | $-307.00K | $-935.70M | $127.67M | (m) | 3 month · $16.98M | (m) | (m) |
| 2020-12-31 | $7.00K | $1.04B | $-270.00K | $-762.75M | $280.97M | (m) | 12 month · $39.04M | (m) | (m) |
| 2020-09-30 | $7.00K | (m) | $-255.00K | $-772.46M | $255.73M | (m) | 3 month · $9.46M | $1.03B | (m) |
| 2020-06-30 | $7.00K | (m) | $-257.00K | $-800.39M | $213.38M | (m) | 3 month · $9.69M | $1.01B | (m) |
| 2020-03-31 | $7.00K | (m) | $50.00K | $-859.43M | $157.28M | (m) | 3 month · $9.95M | $1.02B | (m) |
| 2019-12-31 | $7.00K | $1.00B | $-558.00K | $-895.00M | $105.21M | (m) | 12 month · $35.22M | $1.00B | $105.21M |
| 2019-09-30 | $7.00K | (m) | $-452.00K | $-934.23M | (m) | (m) | 3 month · $9.20M | $990.69M | $56.02M |
| 2019-06-30 | $7.00K | (m) | $-511.00K | $-981.27M | (m) | (m) | 3 month · $8.50M | $977.79M | $-3.98M |
| 2019-03-31 | $7.00K | (m) | $-418.00K | $-1.00B | (m) | (m) | 3 month · $9.81M | $966.73M | $-38.52M |
| 2018-12-31 | $7.00K | (m) | $-282.00K | $-984.83M | $-38.59M | (m) | 12 month · $34.98M | $946.51M | $-38.59M |
| 2018-09-30 | $7.00K | (m) | $-420.00K | $-922.24M | $12.39M | (m) | 3 month · $8.56M | $935.04M | $12.39M |
| 2018-06-30 | $7.00K | (m) | $-537.00K | $-863.43M | $63.17M | (m) | 3 month · $8.69M | $927.13M | $61.83M |
| 2018-03-31 | $6.00K | (m) | $-764.00K | $-819.79M | $-1.79M | (m) | 3 month · $8.72M | $818.75M | $-3.09M |
| 2017-12-31 | $6.00K | (m) | $-750.00K | $-775.49M | $30.54M | (m) | 12 month · $33.40M | $808.06M | $30.54M |
| 2017-09-30 | $6.00K | (m) | $-745.00K | $-726.42M | $56.20M | (m) | (m) | $783.36M | $54.91M |
| 2017-06-30 | $5.00K | (m) | $-673.00K | $-667.44M | $32.14M | (m) | (m) | $700.24M | $30.86M |
| 2017-03-31 | $5.00K | (m) | $-807.00K | $-612.10M | $78.18M | (m) | (m) | $691.08M | $76.96M |
| 2016-12-31 | $5.00K | (m) | $-630.00K | $-537.32M | $20.53M | (m) | 12 month · $27.42M | $558.47M | $19.35M |
| 2016-09-30 | $4.00K | (m) | $-562.00K | $-461.40M | $32.87M | (m) | (m) | $494.83M | $31.72M |
| 2016-06-30 | $4.00K | (m) | $-524.00K | $-545.34M | $-60.89M | (m) | (m) | $484.97M | $-61.95M |
| 2016-03-31 | $4.00K | (m) | $-449.00K | $-475.37M | $-66.01M | (m) | (m) | $409.81M | $-66.88M |
| 2015-12-31 | $4.00K | (m) | $-401.00K | $-409.99M | $-6.21M | (m) | 12 month · $16.71M | $404.18M | $-6.93M |
| 2015-09-30 | $4.00K | (m) | $-473.00K | $-357.59M | $40.57M | (m) | (m) | $398.64M | $40.04M |
| 2015-06-30 | $4.00K | (m) | $-520.00K | $-286.26M | $96.75M | (m) | (m) | $383.52M | $96.36M |
| 2015-03-31 | $3.00K | (m) | $-648.00K | $-227.45M | $38.15M | (m) | (m) | $266.25M | $37.99M |
| 2014-12-31 | $3.00K | (m) | $-525.00K | $-186.72M | $66.80M | (m) | 12 month · $11.12M | $254.05M | $66.76M |
| 2014-09-30 | $1.00K | $5.89M | $-128.00K | $-157.59M | $-151.83M | (m) | (m) | (m) | $-151.99M |
| 2013-12-31 | $1.00K | $2.51M | (m) | $-99.59M | $-97.08M | (m) | 12 month · $2.04M | $2.51M | $-97.08M |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $443.00K | (m) | $-45.50M |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-2.31M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |